DE69131773D1 - Zusammensetzungen und verfahren zur regulierung der rns-aktivität durch abänderung der rns "5'-cap-struktur" - Google Patents

Zusammensetzungen und verfahren zur regulierung der rns-aktivität durch abänderung der rns "5'-cap-struktur"

Info

Publication number
DE69131773D1
DE69131773D1 DE69131773T DE69131773T DE69131773D1 DE 69131773 D1 DE69131773 D1 DE 69131773D1 DE 69131773 T DE69131773 T DE 69131773T DE 69131773 T DE69131773 T DE 69131773T DE 69131773 D1 DE69131773 D1 DE 69131773D1
Authority
DE
Germany
Prior art keywords
rns
cap structure
methods
regulating
modifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69131773T
Other languages
English (en)
Other versions
DE69131773T2 (de
Inventor
Brenda Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69131773D1 publication Critical patent/DE69131773D1/de
Publication of DE69131773T2 publication Critical patent/DE69131773T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69131773T 1990-05-23 1991-05-22 Zusammensetzungen und verfahren zur regulierung der rns-aktivität durch abänderung der rns "5'-cap-struktur" Expired - Fee Related DE69131773T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52759990A 1990-05-23 1990-05-23
PCT/US1991/003606 WO1991017755A1 (en) 1990-05-23 1991-05-22 Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna

Publications (2)

Publication Number Publication Date
DE69131773D1 true DE69131773D1 (de) 1999-12-16
DE69131773T2 DE69131773T2 (de) 2000-03-02

Family

ID=24102143

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131773T Expired - Fee Related DE69131773T2 (de) 1990-05-23 1991-05-22 Zusammensetzungen und verfahren zur regulierung der rns-aktivität durch abänderung der rns "5'-cap-struktur"

Country Status (15)

Country Link
EP (1) EP0531447B1 (de)
JP (1) JPH06500075A (de)
KR (1) KR960004931B1 (de)
AT (1) ATE186464T1 (de)
AU (1) AU649458B2 (de)
BR (1) BR9106486A (de)
CA (1) CA2083377C (de)
DE (1) DE69131773T2 (de)
DK (1) DK0531447T3 (de)
ES (1) ES2139578T3 (de)
FI (1) FI925210A (de)
GR (1) GR3032457T3 (de)
HU (1) HUT63568A (de)
NO (1) NO924309D0 (de)
WO (1) WO1991017755A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
CA2158834C (en) * 1993-04-01 2004-12-07 Brenda F. Baker Antisense oligos which interfere with mrna cap activity and inhibit translation
IL114235A0 (en) * 1994-07-14 1995-10-31 Schering Ag Oligonucleotide conjugates and processes for noninvasive diagnosis utilizing the same
US6380169B1 (en) * 1994-08-31 2002-04-30 Isis Pharmaceuticals, Inc. Metal complex containing oligonucleoside cleavage compounds and therapies
US5962271A (en) * 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
EP1263986A4 (de) * 2000-02-25 2005-02-23 Tao Biosciences Llc Plattform zur Identifikation von bakteriellen Genen welche in der Modifikation von RNA Anwendung finden
JP5645840B2 (ja) 2008-12-02 2014-12-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ リン原子修飾核酸の合成方法
JP5998326B2 (ja) 2009-07-06 2016-09-28 ウェイブ ライフ サイエンス リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 新規核酸プロドラッグおよびその使用方法
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
MX347361B (es) 2011-07-19 2017-04-12 Wave Life Sciences Ltd Metodos para la sintesis de acidos nucleicos funcionalizados.
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
WO2014010718A1 (ja) 2012-07-13 2014-01-16 株式会社新日本科学 キラル核酸アジュバント
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095460A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum
EP3095461A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäure-adjuvans mit immunitätsinduktionswirkung und immunitätsinduktionsaktivator
SG10201912897UA (en) 2014-01-16 2020-02-27 Wave Life Sciences Ltd Chiral design

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
BR9105935A (pt) * 1990-01-11 1992-11-17 Isis Pharmaceuticals Inc Composicao,analogo de oligonucleotideo,oligonucleotideo sequenciado misto,processo para a preparacao de nucleosideos 2'-substituidos,composicao para modular a atividade de rna,processos para modular a producao de uma proteina por um organismo,para tratar um animal,para detectar a presenca ou ausencia de rna,oligonucleotideo ou analogo de analogo de oligonucleotideo resistente a nuclease e processo para tratar um organismo tendo uma doenca

Also Published As

Publication number Publication date
DK0531447T3 (da) 2000-03-27
CA2083377C (en) 2002-11-26
WO1991017755A1 (en) 1991-11-28
ATE186464T1 (de) 1999-11-15
FI925210A0 (fi) 1992-11-17
HU9203659D0 (en) 1993-04-28
HUT63568A (en) 1993-09-28
BR9106486A (pt) 1993-05-25
DE69131773T2 (de) 2000-03-02
KR930700118A (ko) 1993-03-13
KR960004931B1 (ko) 1996-04-18
FI925210A (fi) 1992-11-17
NO924309L (no) 1992-11-09
EP0531447A4 (en) 1993-08-11
CA2083377A1 (en) 1991-11-24
EP0531447B1 (de) 1999-11-10
EP0531447A1 (de) 1993-03-17
NO924309D0 (no) 1992-11-09
JPH06500075A (ja) 1994-01-06
ES2139578T3 (es) 2000-02-16
AU8080291A (en) 1991-12-10
GR3032457T3 (en) 2000-05-31
AU649458B2 (en) 1994-05-26

Similar Documents

Publication Publication Date Title
DE69131773D1 (de) Zusammensetzungen und verfahren zur regulierung der rns-aktivität durch abänderung der rns "5'-cap-struktur"
DE3280400D1 (de) Oligonukleotides heilmittel und dessen herstellungsverfahren.
IT8619684A0 (it) Preparato di acido ialuronico chimicamente modificato e metodo per recuperarlo da tessuti animali.
MX9602993A (es) Hormona del crecimiento humano.
DE69433626D1 (de) N-2 substituierte purine
PL334530A1 (en) Novel genes specific in respect to n-axecetyl-l-phosphotricin, used to code amino acids deacetylase, their isolation and application
BR9106751A (pt) Oligonucleotideo ou analogo de nucleotideo e processo para modulacao da atividade de uma infeccao por citomegalovirus
ATE323510T1 (de) Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen
NZ531570A (en) DNA sequences for human angiogenesis genes
ATE230439T1 (de) Gezielte gentherapie
PT1053313E (pt) Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase
DE69729145D1 (de) Reagenz und Verfahren zur Inhibierung der N-RAS Expression
ATE342067T1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
ATE222601T1 (de) Methode zur expression in und isolation von biologisch aktiven molekülen aus urin
ATE218372T1 (de) Antisense oligonnukleotide die mit der mrna cap aktivität interferieren und die translation inhibieren
EP0592685A4 (de) Planze resistent gegen mindestens zwei viren und dessen preparation.
DE69433996D1 (de) Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten
ATE164882T1 (de) Verfahren zur herstellung von aktivierten killer- monozyten und verfahren zur überprüfung ihrer tumoriziden aktivität
Dawid et al. Gene expression in amphibian embryogenesis
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
ATE65543T1 (de) Dna-sequenzen des ebv-genoms, rekombinante dnamolek¨le, verfahren zur herstellung von ebvverwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: VONNEMANN, KLOIBER & KOLLEGEN, 80796 MUENCHEN

8339 Ceased/non-payment of the annual fee